Long-term safety of growth hormone deficiency treatment in cancer and sellar tumors adult survivors: is there a role of gh therapy on the neoplastic risk?

HIGHLIGHTS

SUMMARY

Reference Study Group Arslanian et_al, 1985 34 CNS tumors: Germinomas, craniopharyngiomas, astrocytomas, medulloblastomas, others; 94% GHD New Malignancy/Recurrence GH-treated (24/34): 8 (33%) recurrences. Cases expected: 6.96-9.28 Leung et_al, 2002 47 CCS after ALL with GHD and treated with GH for 1 to 8 years. Control group: 544 CCS after ALL, non-GH treated GH-treated: 1 case of sclerosing sweat duct carcinoma of the scalp, 1 case of myelodysplastic syndrome, no cases of leukemia recurrence Sklar et_al, 2002 CCS: 361 treated with GH for 4.6 years. Ergun . . .

 



If you want to have access to all the content you need to log in!

Thanks :)

Username or Email

Password

Remember me

Lost your password?

If you don't have an account, you can create one here.